Analytical Data
-
Gene name
IGLV2-14
- Application
-
Alternative Names
IGLV2-14Immunoglobulin lambda variable 2-14; Ig lambda chain V-II region NIG-84; Ig lambda chain V-II region TOG; Ig lambda chain V-II region VIL
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01704
-
Expression Region
1-230aa
-
AA Sequence
MSVLPGPLSQAVLTQPSSLSASPGASASLTCTLRRGFYVYDYRIYWYQQKSGRSPQYLLRHRSDSDKQQGSGVPSRFSGSKDASANAGILVISGLRSEDEADYYCMVWHNSAWVFGGGTRLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS
-
Molecular Weight
51.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The IGLV2-14 gene, part of the immunoglobulin light chain variable gene family, is crucial for the adaptive immune response, specifically in the production of antibodies. Research on IGLV2-14 recombinant proteins has gained significance due to their potential applications in therapeutic antibody development and diagnostics. As an essential component of immunoglobulin synthesis, variations and mutations in the IGLV genes can influence antibody diversity and specificity. Understanding the structure and function of IGLV2-14 may facilitate the design of monoclonal antibodies with enhanced binding affinities for antigens, including pathogens and tumors. Furthermore, recombinant IGLV2-14 proteins can serve as valuable tools in elucidating antibody responses in various diseases and for vaccine development. Advances in molecular cloning and protein expression technologies have enabled the production of IGLV2-14 proteins in various systems, allowing for detailed characterization and functional studies. This research is pivotal not only in the field of immunology but also in developing strategies to combat infectious diseases and cancer, highlighting the relevance of IGLV2-14 in current biomedical research and its potential to contribute to personalized medicine.











